

## **ADAP UPDATE!!**

The following changes have been made to the to the ADAP formulary effective February 2008:

The following medication has been added to the ADAP formulary:

### **Non-Nucleoside Reverse Transcriptase Inhibitor**

Etravirine (**Intelence**) Exception Criteria: *NRTI and first line NNRTI (delavirdine, efavirenz, or nevirapine) experienced or contraindicated, with either a detectable viral load or intolerance to current regimen.* ADAP Medication Exception Form documenting authorized indications in the “Reason for Exception” section. [Medication Exception Form required](#) only with the *initial* prescription.

Note: Clients who have participated in the etravirine clinical trial or expanded access program will be eligible to receive the medication. Clinicians will need to indicate study participation under “Reason for Exception” on the ADAP Medication Exception Form.

The medication exception criteria has changed for the following medication:

raltegravir (**Isentress**)

*“NRTI and NNRTI experienced or contraindicated with either a detectable viral load or intolerance to current regimen or prior experience with 1 or more PIs.”*

The medication exception criteria have changed for the following medications:

darunavir (**Prezista**)  
enfuvirtide (**Fuzeon**)  
tipranavir (**Aptivus**)

*“NRTI and NNRTI experienced or contraindicated, with either a detectable viral load or intolerance to current regimen, and prior experience with 1 or more PIs.”*